



**SOLARA**  
Active Pharma Sciences

Communication Address :  
**Solara Active Pharma Sciences Limited**  
Batra Centre  
No. 28, Sardar Patel Road, Post Box 2630  
Guindy, Chennai - 600 032, India  
Tel : +91 44 43446700, 22207500  
Fax : +91 44 22350278

July 8, 2019

The BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E), Mumbai – 400 051

Scrip Code: 541540

Scrip Code: SOLARA

Dear Sir / Madam,

**Sub:** Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

We are enclosing herewith a press release issued by the Company titled:

***“Solara Cuddalore facility completes USFDA Inspection with zero 483s”***

Thanking you,

Thanking you,

Yours faithfully,  
**For Solara Active Pharma Sciences Limited**

**S. Murali Krishna**  
Company Secretary

Encl:- as above



## Solara's Cuddalore facility completes USFDA Inspection with ZERO 483s

---

**Chennai, India – July 8, 2019:** Solara Active Pharma Science Limited (Solara), a leading Active Pharmaceutical Ingredient provider today announced the successful completion of US FDA inspection at the multi-product manufacturing facility at Cuddalore with ZERO 483s inspectional observations.

The Cuddalore multi-product API manufacturing facility was established in the year 1991 and is equipped with appropriate infrastructure to include several independent production blocks and related packaging sections. This site is inspected by various Regulatory Authorities including US FDA, MHRA, EDQM, WHO, PMDA, TGA, KFDA, and COFEPRIS. The current US FDA inspection at the facility was scheduled and completed between 1<sup>st</sup> July and 5<sup>th</sup> July 2019.

Solara continues to stay focused on maintaining the highest level of compliance across its manufacturing facilities. This is Company's third consecutive US FDA audit with "Zero 483s". In Dec'18 and Jan'19, the company also completed US FDA inspections at Solara Research Centre(SRC), Chennai and Ambernath manufacturing facility with zero 483s.

### About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) headquartered in Bengaluru, India offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising five API facilities in India with approvals including the USFDA, EU GMP, KFDA and PMDA in Japan.

#### Investor / Analyst contact

**Dikshita Jain**

**Christensen Investor Relations**

✉ [djain@christensenir.com](mailto:djain@christensenir.com)

☎ +91 22 4215 0210

#### Statutory contact

**Murali Krishna S**

**Raghavan. V**

✉ [investors@solara.co.in](mailto:investors@solara.co.in)

☎ +91 44 4344 6700

*Disclaimer: Certain statements in this document that are not historical facts are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*

